» Articles » PMID: 10741912

Nephrotoxicity of Ifosfamide, Carboplatin and Etoposide (ICE) Alone or Combined with Extracorporeal or Radiant-heat-induced Whole-body Hyperthermia

Overview
Specialty Oncology
Date 2000 Mar 31
PMID 10741912
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Although whole-body hyperthermia combined with specific genotoxic chemotherapy can be shown to enhance neoplastic cell killing without a concomitant rise in bone marrow toxicity, nephrotoxicity can become treatment-limiting. This study compares the kidney toxicity to the kidney of ifosfamide, carboplatin and etoposide (ICE) chemotherapy alone, and ICE chemotherapy combined with either extracorporeal (e-WBH) or radiant-heat-induced hyperthermia (r-WBH) in 43 patients with refractory sarcoma. Within 3 days of ICE chemotherapy treatment there was a significant increase in urinary protein excretion and a reduction of the glomerular filtration rate. These effects were more pronounced if WBH was added. The use of immunoluminometric assays revealed a predominance of low-molecular-mass proteins. This increase in protein excretion persisted in the e-WBH-treated group, whereas it vanished within 3 weeks in both the group treated with ICE alone and that treated with r-WBH. Our findings suggest that ICE chemotherapy causes transient tubular and glomerular damage, which is enhanced by WBH. In terms of long-term nephrotoxicity e-WBH was more nephrotoxic than r-WBH. This finding is consistent with our clinical observations.

Citing Articles

Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Kooijmans E, Bokenkamp A, Tjahjadi N, Tettero J, van Dulmen-den Broeder E, van der Pal H Cochrane Database Syst Rev. 2019; 3:CD008944.

PMID: 30855726 PMC: 6410614. DOI: 10.1002/14651858.CD008944.pub3.


Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma.

Okada S, Hongo T, Sakaguchi K, Suzuki K, Nishizawa S, Ohzeki T Childs Nerv Syst. 2007; 23(4):407-13.

PMID: 17226035 DOI: 10.1007/s00381-006-0282-5.


Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

Kangarloo S, Gangopadhyay S, Syme R, Wolff J, Gluck S Med Oncol. 2004; 21(1):9-20.

PMID: 15034209 DOI: 10.1385/MO:21:1:09.